Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M et al.
N Engl J Med 2024; 391: 1696-1708.
The addition of neoadjuvant ipilimumab to the current postoperative regimen improved 12-month event free survival from 57.2 to 83.7 per cent, P<0.001, in this study that included 423 patients.
Comment: Further progress towards an optimal approach.
.png)
.jpg){kind=logo}
